Dinutuximab beta is a monoclonal antibody used to treat neuroblastoma, a type of cancer that affects the nervous system. It is administered in combination with chemotherapy and works by targeting the GD2 antigen on neuroblastoma cells, which helps to slow or stop the growth of the cancer. It is given intravenously (through a vein) and is typically used in children over the age of 1 year. Side effects of Dinutuximab beta can include fever, chills, nausea, vomiting, constipation, headache, and rash.
Dinutuximab beta, also known by the trade name Qarziba, is a medication used to treat high-risk neuroblastoma in children aged 12 months and above. It is a type of immunotherapy drug known as a monoclonal antibody. Monoclonal antibodies are laboratory-made proteins that can identify and bind to specific cells or substances in the body. Dinutuximab beta works by binding to a sugar molecule called GD2 that is found on the surface of neuroblastoma cells. Once attached, the immune system is able to recognize and destroy the cancer cells.
Dinutuximab beta is typically given as a series of infusions over a period of several weeks. It is important to note that this medication can cause serious side effects, including pain, fever, chills, fatigue, nausea, vomiting, diarrhea, and allergic reactions. Dinutuximab beta is only available in a hospital setting and should be given under the supervision of a qualified healthcare professional.